Cancer Immunotherapy Market

Cancer Immunotherapy Market by Products (Monoclonal Antibodies, Immunomodulators, and Oncolytic Viral Therapies & Cancer Vaccines), Cancer Types (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Ovarian Cancer, and Pancreatic Cancer), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1892
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 190
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global cancer immunotherapy market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the developing advanced cancer treatment facilities and lowering the rate of tumor recurrence after chemotherapy.

Cancer Immunotherapy Market Key Takeaways

Immunotherapy, also known as biologic therapy, is a major type of therapy method used for the cancer treatment. The therapy is based on improving a patient’s immune system to help fight against cancer by either pushing to build a person's own immune system or injecting body's immune components including man-made immune system proteins. Rising R&D activity in the field of cancer immunotherapy is leading to the development of advanced therapy versions with improved and effective treatments. Immuno-oncology has showed encouraging results in terms of increased survival and decreased toxicity. Immunotherapies in development are expected to offer additional treatment options and better outcomes than currently available medicines.

Furthermore, the introduction of additional medication classes, including monoclonal antibodies and histone deacetylase (HDAC) inhibitors are aimed to meet the needs for targeting multiple myeloma receptors. The market is expected to grow due to ongoing research on similar drugs with the goal of reducing side effects. The market growth is further accelerated due to the growing approval of several techniques and therapy methods including PD-1 and CTLA-4 checkpoint inhibitors for melanoma. Meanwhile, innovative immunotherapy medication formulations including as vaccines and adjuvants, are gaining popularity over the years. Furthermore, more immunotherapies, such as immunomodulators and CAR T-cell treatment, are being investigated for improved outcomes.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing prevalence of cancer and increasing cancer therapy facilities coupled with rising awareness of the existing cancer treatment methods are key factors driving the market growth.
  • Rising activities related to R&D programs and technological developments in treatment options are projected to boost the market growth during the forecast period.
  • Increasing approvals of cancer therapy products and favorable government policies encouraging the development of innovative cancer treatment are expected to propel market growth during the forecast period.
  • Showing resistance to chemotherapy & side-effects using radiation therapy for the cancer treatment are key challenges that can restrain the market expansion.
  • High cost of cancer therapies and limited information on cancer immunobiology are restraining factors hampering the market growth.

Scope of the Report

The report on the global cancer immunotherapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cancer Immunotherapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Monoclonal Antibodies, Immunomodulators, and Oncolytic Viral Therapies & Cancer Vaccines), and Cancer Types (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Ovarian Cancer, and Pancreatic Cancer)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Amgen Inc.; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Co.; Merck and Co.; Novartis; and Pfizer, Inc.

Market Segment Insights

Monoclonal antibodies segment is projected to account for a key market share

On the basis of products, the global cancer immunotherapy market is divided into monoclonal antibodies, immunomodulators, and oncolytic viral therapies & cancer vaccines. The monoclonal antibodies segment is projected to account for a key share of the market during the forecast period owing to increasing R&D programs for monoclonal antibodies such as conjugated monoclonal antibodies and bispecific antibodies. On the other hand, the immunomodulators segment is anticipated to upsurge the market considerably in coming years owing to the wide adoption of Immunotherapy medications. These medications are extensively used to modify a patient's immune system, hence increasing the immune system's ability to fight malignancies. The rising market penetration of these immunomodulatory medicines is due to their increasing efficacy and accuracy.

Melanoma segment is expected to grow at a significant pace

Based on cancer types, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, ovarian cancer, and pancreatic cancer. The melanoma segment is expected to grow at a significant pace during the forecast period owing to wide approval of melanoma treatment medicines and development of several antibodies such as monoclonal antibodies and checkpoint inhibitors. Monoclonal antibodies can effectively block tumor cells from forming new blood vessels, allowing for the inhibition of an alternative avenue for tumor cell proliferation. Furthermore, in individuals with advanced lung cancer, checkpoint inhibitors are utilized as a first-line treatment.

However, the lung cancer segment is projected to exhibit a high CAGR during the forecast period owing to wide availability of immunotherapeutic medications such as Opdivo, Keytruda, and Tecentriq. Moreover, rising approved for lung cancer treatment products and typically recommended when a tumor recurs after chemotherapy are propelling the segment growth.

Cancer Immunotherapy Market By Cancer Types

Asia Pacific is anticipated to dominate the market

On the basis of regions, the global cancer immunotherapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to dominate the market by expanding at an impressive during the forecast period. The regional market growth is attributed to the increasing use of immunotherapy for tumor treatment due to approval of new therapeutic medications in China and Japan.

However, North America held a large revenue share in 2019 and is anticipated to register a substantial growth rate in the coming years. Rising incidence of cancer, increasing development of modern therapeutics methods, and growing geriatric population are contributing to the growth of the regional market. Several clinical trials are now underway as well as the Food and Drug Administration’s approvals for new therapeutic compounds and combination medicines are other major drivers for the market.

Cancer Immunotherapy Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Immunotherapy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cancer Immunotherapy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cancer Immunotherapy Market - Supply Chain
  4.5. Global Cancer Immunotherapy Market Forecast
     4.5.1. Cancer Immunotherapy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cancer Immunotherapy Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cancer Immunotherapy Market Absolute $ Opportunity
5. Global Cancer Immunotherapy Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Cancer Immunotherapy Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Cancer Immunotherapy Demand Share Forecast, 2019-2026
6. North America Cancer Immunotherapy Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Cancer Immunotherapy Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Cancer Immunotherapy Demand Share Forecast, 2019-2026
7. Latin America Cancer Immunotherapy Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Cancer Immunotherapy Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Cancer Immunotherapy Demand Share Forecast, 2019-2026
8. Europe Cancer Immunotherapy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Cancer Immunotherapy Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Cancer Immunotherapy Demand Share Forecast, 2019-2026
9. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Cancer Immunotherapy Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Cancer Immunotherapy Demand Share Forecast, 2019-2026
10. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Cancer Immunotherapy Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Cancer Immunotherapy Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Cancer Immunotherapy Market: Market Share Analysis
  11.2. Cancer Immunotherapy Distributors and Customers
  11.3. Cancer Immunotherapy Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Amgen Inc. AstraZeneca F. Hoffman La Roche Bayer AG Bristol-Myers Squibb Eli Lilly and Co. &
Segments Covered in the Report
The global cancer immunotherapy market has been segmented on the basis of

Products
  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies & Cancer Vaccines
Cancer Types
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffman La Roche
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly and Co.
  • Merck and Co.
  • Novartis
  • Pfizer, Inc.

Key players competing in the cancer immunotherapy market are Amgen Inc.; AstraZeneca; F. Hoffman La Roche; Bayer AG; Bristol-Myers Squibb; Eli Lilly and Co.; Merck and Co.; Novartis; and Pfizer Inc.

These companies are implementing strategies such as technological advancements, innovative solution, new developed product launches, research initiatives, merger & acquisitions, and regional expansions to secure their advantageous position in the cancer immunotherapy market. Furthermore, rapid acceptance of sophisticated treatment alternatives for enhanced healthcare as well as the growing requirement for optimal capital usage, are key factors influencing competitiveness.

Cancer Immunotherapy Market By Key Players

Buy Report